We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
India’s Glenmark is rolling all of the new molecular entities (NMEs) in its pipeline into a separate U.S. company in an effort to speed the programs to market.